|
Post by boca1girl on Oct 5, 2017 12:16:32 GMT -5
I also went into the Black today just under $5 average. What a difference 2 weeks make.
If we hold above that magic $5 mark, we should see more institutional buying.
The rally this morning was breath taking! But I believe we have much more to come over the next few years.
|
|
|
Post by lakers on Oct 5, 2017 12:25:42 GMT -5
Big Pharmas are smart. Once they realize A has a good chance to redefine standard of care, no doubt they will swoop in, from my experience. They won't wait till script hits 5K/wk. Now that Novo popularized Fiasp Fast acting, made it sexy, fashionable, trendy, hip, glamorous, other Pharmas gonna trip over themselves to one up that. The only thing that handily beats Fiasp for bolus whether injectable or non injectable is A.
A is mucho more sexy, fashionable, trendy, hip, glamorous, Hollywood, and effective than Fiasp ever dreams of, which sounds like Fiasco, btw.
Despite all that, A is even more practical and cheaper. Let's not forget Mex, Can, U.S. Are NAFTA buddies. That means no tariff, low shipping cost (we share borders. no wall built yet), no refrigeration if used within 30 days.
Of course, BoD (reversed shark tank) will play hard to get maybe accepting $0.5 B for 5% stake, or $10B valuation ($60 ish Pps).
Thank you, Denmark, for your reversed Marshall plan.
To imitate peppy, BPs would look at each other saying Oh chit, we can't let Fiasp dominate the fast acting bolus market, what we gonna do?? Developing Fiasp's Daddy from scratch would take at least $3B, 12 years to gain good FDA approval with no guarantee for success. You know what BPs would do as any smart biz people.
|
|
|
Post by seanismorris on Oct 5, 2017 12:36:39 GMT -5
I also went into the Black today just under $5 average. What a difference 2 weeks make. If we hold above that magic $5 mark, we should see more institutional buying. The rally this morning was breath taking! But I believe we have much more to come over the next few years. I agree. That’s why tomorrow’s scripts number is especially important. If scripts is just so-so, we could see consolidation at $5; in other words stuck in the mud for a while. If scripts are bad, we could loose 15% as people take profits. And, of course bringing us below $5 where institutions loose interest. If scripts are good, we’ll break through $6 next week. If we can get can get consecutive weeks of ‘good’ MNKD will double by the end of the month. Note: my standard of ‘good’ is apparently higher than most others here. The problem is we won’t see an impact on scripts (from the Label change) for several weeks. So, MannKind is going into Friday’s big fight with one hand tied behind their back. Fingers crossed.
|
|
|
Post by humann on Oct 5, 2017 12:39:52 GMT -5
I hope no one is expecting scripts to increase immediately on label news. I have to think the rising PPS has more to do with an expectation that Mannkind has a better chance at a successful future now.
|
|
|
Post by dreamboatcruise on Oct 5, 2017 12:40:38 GMT -5
Big Pharmas are smart. Once they realize A has a good chance to redefine standard of care, no doubt they will swoop in, from my experience. They won't wait till script hits 5K/wk. Now that Novo popularized Fiasp Fast acting, made it sexy, fashionable, trendy, hip, glamorous, other Pharmas gonna trip over themselves to one up that. The only thing that handily beats Fiasp for bolus whether injectable or non injectable is A. A is mucho more sexy, fashionable, trendy, hip, glamorous, Hollywood, and effective than Fiasp ever dreams of, which sounds like Fiasco, btw. Despite all that, A is even more practical and cheaper. Let's not forget Mex, Can, U.S. Are NAFTA buddies. That means no tariff, low shipping cost (we share borders. no wall built yet), no refrigeration if used within 30 days. Of course, BoD (reversed shark tank) will play hard to get maybe accepting $0.5 B for 5% stake, or $10B valuation ($60 ish Pps). Thank you, Denmark, for your reversed Marshall plan. To imitate peppy, BPs would look at each other saying Oh chit, we can't let Fiasp dominate the fast acting bolus market, what we gonna do?? Developing Fiasp's Daddy from scratch would take at least $3B, 12 years to gain good FDA approval with no guarantee for success. You know what BPs would do as any smart biz people. I suspect you're getting a bit ahead of reality on Fiasp. I'd guess that awareness of Fiasp among those with diabetes in US is around the same as Afrezza... LOW. Of course you're also getting ahead of reality on things like refrigeration requirement of Afrezza. BTW Lily already has there own version of Fiasp (I think supposed to be even quicker, though still unlikely to match Afrezza) that they slate to hit market in 2019, so others haven't been sitting waiting and now caught off guard.
|
|
|
Post by dreamboatcruise on Oct 5, 2017 12:42:04 GMT -5
I also went into the Black today just under $5 average. What a difference 2 weeks make. If we hold above that magic $5 mark, we should see more institutional buying. The rally this morning was breath taking! But I believe we have much more to come over the next few years. I agree. That’s why tomorrow’s scripts number is especially important. If scripts is just so-so, we could see consolidation at $5; in other words stuck in the mud for a while. If scripts are bad, we could loose 15% as people take profits. And, of course bringing us below $5 where institutions loose interest. If scripts are good, we’ll break through $6 next week. If we can get can get consecutive weeks of ‘good’ MNKD will double by the end of the month. Note: my standard of ‘good’ is apparently higher than most others here. The problem is we won’t see an impact on scripts (from the Label change) for several weeks. So, MannKind is going into Friday’s big fight with one hand tied behind their back. Fingers crossed. What's good in your opinion... 5% increase, 10%... 20%?
|
|
|
Post by babaoriley on Oct 5, 2017 12:43:33 GMT -5
A rising share price will make all else look rosy (beer googles). Still hoping for a buyout, one and done!
|
|
|
Post by dreamboatcruise on Oct 5, 2017 12:46:09 GMT -5
|
|
|
Post by babaoriley on Oct 5, 2017 12:48:07 GMT -5
Lizard, you're acting like a chameleon!
|
|
|
Post by lakers on Oct 5, 2017 12:49:38 GMT -5
With Novo's Mktg machine, they would make fast acting popular. The tide that raises all boats including your own dream boat. A just happens to be the fastest speed boat which is not a dream but here and now!
You get way ahead of yourself in Lily's 2019 dream boat, my colleague! First mover advantage if commercialized well can be worth a lot.
Novo already made Fast acting hip and popular. See Lily.
|
|
|
Post by liane on Oct 5, 2017 12:52:14 GMT -5
A rising share price will make all else look rosy (beer googles). Still hoping for a buyout, one and done! Bite your tongue!
|
|
|
Post by ilovekauai on Oct 5, 2017 12:52:39 GMT -5
I have a way to go for my break even. That r/s was such a disappointment. My hope is that once the ship is righted that a forward split will happen.
|
|
|
Post by dreamboatcruise on Oct 5, 2017 12:56:26 GMT -5
Lizard, you're acting like a chameleon! I'm still wanting to ride this for several years. Also... I'm thrilled with the increase of the past week, and getting much closer to my roughly $8.25 break even point, but much of my earlier purchases were in retirement accounts. My more recent near bottom buys of calls that are all now nicely profitable were my trading account. So if we got bought out now I'd still have a big loss in retirement accounts where it doesn't even help offset the gains for tax purposes. I'm willing to be patient... need it back up over $20 to recoup my retirement savings. So... this lizard is hissing at any near term buyout.
|
|
|
Post by lakers on Oct 5, 2017 12:58:05 GMT -5
A rising share price will make all else look rosy (beer googles). Still hoping for a buyout, one and done! Bite your tongue! Any deal is possible if the offer is great enough, especially when both sides think they screwed the other. The Art of the Deal! Remember People Soft and Oracle?? I agree with Baba.
|
|
|
Post by radgray68 on Oct 5, 2017 13:00:42 GMT -5
A rising share price will make all else look rosy (beer googles). Still hoping for a buyout, one and done! For Al Mann's sake, may God rest his beautiful, genius soul, I would hope they put in a clause in any sale that says we get back Afrezza if it is not made available globally within a reasonable time frame. Al wanted diabetics to have this tool and Mannkind should settle for nothing less. As far as a sale goes, BP would have to pay up BIG TIME for me right now. But, that'd mean they would be very motivated to get it out there.
|
|